CL2015003496A1 - Anticuerpos teicoicos anti-pared y conjugados. - Google Patents
Anticuerpos teicoicos anti-pared y conjugados.Info
- Publication number
- CL2015003496A1 CL2015003496A1 CL2015003496A CL2015003496A CL2015003496A1 CL 2015003496 A1 CL2015003496 A1 CL 2015003496A1 CL 2015003496 A CL2015003496 A CL 2015003496A CL 2015003496 A CL2015003496 A CL 2015003496A CL 2015003496 A1 CL2015003496 A1 CL 2015003496A1
- Authority
- CL
- Chile
- Prior art keywords
- wall
- therapeutic anti
- conjugate antibodies
- conjugate
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361829461P | 2013-05-31 | 2013-05-31 | |
US201361829466P | 2013-05-31 | 2013-05-31 | |
US14/284,609 US20140356375A1 (en) | 2013-05-31 | 2014-05-22 | Anti-wall teichoic antibodies and conjugates |
PCT/US2014/039113 WO2014193722A1 (en) | 2013-05-31 | 2014-05-22 | Anti-wall teichoic antibodies and conjugates |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2015003496A1 true CL2015003496A1 (es) | 2016-12-23 |
Family
ID=51989438
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2015003496A CL2015003496A1 (es) | 2013-05-31 | 2015-11-30 | Anticuerpos teicoicos anti-pared y conjugados. |
Country Status (30)
Country | Link |
---|---|
EP (2) | EP3004162B1 (es) |
JP (2) | JP6469094B2 (es) |
KR (1) | KR20160015227A (es) |
CN (2) | CN105358573B (es) |
AU (2) | AU2014273939B2 (es) |
BR (1) | BR112015029838A2 (es) |
CA (1) | CA2910029A1 (es) |
CL (1) | CL2015003496A1 (es) |
CR (1) | CR20150626A (es) |
DK (1) | DK3004162T3 (es) |
EA (1) | EA201592078A1 (es) |
ES (1) | ES2793174T3 (es) |
HK (1) | HK1220982A1 (es) |
HR (1) | HRP20200812T1 (es) |
HU (1) | HUE050451T2 (es) |
IL (1) | IL242175B (es) |
LT (1) | LT3004162T (es) |
MA (1) | MA38686A1 (es) |
MX (2) | MX369022B (es) |
MY (1) | MY177774A (es) |
PE (1) | PE20160715A1 (es) |
PH (1) | PH12015502636A1 (es) |
PL (1) | PL3004162T3 (es) |
PT (1) | PT3004162T (es) |
RS (1) | RS60256B1 (es) |
SG (1) | SG11201509839TA (es) |
SI (1) | SI3004162T1 (es) |
UA (1) | UA120088C2 (es) |
WO (1) | WO2014194247A1 (es) |
ZA (1) | ZA201507977B (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160015286A (ko) | 2013-05-31 | 2016-02-12 | 제넨테크, 인크. | 항-세포벽 테이코산 항체 및 접합체 |
NZ720743A (en) | 2013-12-16 | 2021-12-24 | Medimmune Ltd | Peptidomimetic compounds and antibody-drug conjugates thereof |
JP6895254B2 (ja) | 2013-12-16 | 2021-06-30 | ジェネンテック, インコーポレイテッド | ペプチド模倣化合物及びその抗体−薬物コンジュゲート |
IL285102B2 (en) * | 2014-09-11 | 2024-06-01 | Seagen Inc | Targeted administration of medicinal substances containing a tertiary amine |
WO2016090040A1 (en) | 2014-12-03 | 2016-06-09 | Genentech, Inc. | Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof |
JP6742314B2 (ja) | 2014-12-03 | 2020-08-19 | ジェネンテック, インコーポレイテッド | 抗黄色ブドウ球菌抗体リファマイシン複合体及びその使用 |
WO2016090050A1 (en) * | 2014-12-03 | 2016-06-09 | Genentech, Inc. | Quaternary amine compounds and antibody-drug conjugates thereof |
EP3307780A1 (en) * | 2015-06-15 | 2018-04-18 | Genentech, Inc. | Antibodies and immunoconjugates |
AU2016363013B2 (en) | 2015-12-04 | 2022-03-10 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
US10336683B2 (en) * | 2016-03-04 | 2019-07-02 | Genentech, Inc. | Process for the preparation of an antibody-rifamycin conjugate |
US20200123237A1 (en) | 2016-05-18 | 2020-04-23 | Genmab B.V. | Antibodies and methods of use thereof in treatment of infectious disease |
EP3464280B1 (en) | 2016-06-06 | 2021-10-06 | F. Hoffmann-La Roche AG | Silvestrol antibody-drug conjugates and methods of use |
JP2020533308A (ja) | 2017-09-08 | 2020-11-19 | シアトル ジェネティックス, インコーポレイテッド | チューブリシンおよびそれらの中間体の調製のためのプロセス |
US11857638B2 (en) | 2018-07-27 | 2024-01-02 | Promega Corporation | Quinone-containing conjugates |
WO2021195716A1 (en) * | 2020-04-02 | 2021-10-07 | Monash University | Antibiotic conjugates |
GB202214756D0 (en) * | 2022-10-07 | 2022-11-23 | Univ Oxford Innovation Ltd | Product |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB877732A (en) | 1958-08-12 | 1961-09-20 | Lepetit Spa | The antibiotic rifomycin, its components and methods of preparing same |
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4867973A (en) * | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
US4610919A (en) | 1985-06-14 | 1986-09-09 | Fiber Bond Corporation | Binder for fibrous padding |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
JP2544375B2 (ja) | 1986-07-14 | 1996-10-16 | 鐘淵化学工業株式会社 | アルキル置換ベンゾキサジノリフアマイシン誘導体 |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
CA1304363C (en) | 1988-11-01 | 1992-06-30 | Takehiko Yamane | 3'-hydroxybenzoxazinorifamycin derivative, process for preparing the same and antibacterial agent containing the same |
EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
US5362852A (en) | 1991-09-27 | 1994-11-08 | Pfizer Inc. | Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties |
US6660267B1 (en) | 1992-12-21 | 2003-12-09 | Promega Corporation | Prevention and treatment of sepsis |
US5545721A (en) | 1992-12-21 | 1996-08-13 | Ophidian Pharmaceuticals, Inc. | Conjugates for the prevention and treatment of sepsis |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
US5981522A (en) | 1995-09-01 | 1999-11-09 | Kaneka Corporation | Treatment of disease caused by infection of Helicobacter |
JP3963976B2 (ja) | 1995-12-08 | 2007-08-22 | 株式会社カネカ | クラミジア感染症治療剤 |
US6322788B1 (en) | 1998-08-20 | 2001-11-27 | Stanley Arthur Kim | Anti-bacterial antibodies and methods of use |
ES2571230T3 (es) | 1999-04-09 | 2016-05-24 | Kyowa Hakko Kirin Co Ltd | Procedimiento para controlar la actividad de una molécula inmunofuncional |
AU5867100A (en) | 1999-05-03 | 2000-12-12 | Medarex, Inc. | Human antibodies to staphylococcus aureus |
JP4668498B2 (ja) | 1999-10-19 | 2011-04-13 | 協和発酵キリン株式会社 | ポリペプチドの製造方法 |
CN102311986B (zh) | 2000-10-06 | 2015-08-19 | 协和发酵麒麟株式会社 | 产生抗体组合物的细胞 |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
WO2003026577A2 (en) | 2001-09-24 | 2003-04-03 | Seattle Genetics, Inc. | P-amidobenzylethers in drug delivery agents |
AU2002337935B2 (en) | 2001-10-25 | 2008-05-01 | Genentech, Inc. | Glycoprotein compositions |
CA2467242A1 (en) | 2001-11-20 | 2003-05-30 | Seattle Genetics, Inc. | Treatment of immunological disorders using anti-cd30 antibodies |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
AU2003236020B2 (en) | 2002-04-09 | 2009-03-19 | Kyowa Hakko Kirin Co., Ltd. | Cell with depression or deletion of the activity of protein participating in GDP-fucose transport |
AU2003236018A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa |
JPWO2003084569A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物含有医薬 |
US20050031613A1 (en) | 2002-04-09 | 2005-02-10 | Kazuyasu Nakamura | Therapeutic agent for patients having human FcgammaRIIIa |
CN102911987B (zh) | 2002-04-09 | 2015-09-30 | 协和发酵麒麟株式会社 | 基因组被修饰的细胞 |
WO2003085118A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Procede de production de composition anticorps |
WO2004010957A2 (en) | 2002-07-31 | 2004-02-05 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
US20050180972A1 (en) | 2002-07-31 | 2005-08-18 | Wahl Alan F. | Anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders |
US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
WO2004042072A2 (en) | 2002-11-01 | 2004-05-21 | The Regents Of The University Of Colorado, A Body Corporate | Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry |
WO2004050846A2 (en) * | 2002-12-02 | 2004-06-17 | Biosynexus Incorporated | Wall teichoic acid as a target for anti-staphylococcal therapies and vaccines |
BRPI0316779B1 (pt) | 2002-12-16 | 2020-04-28 | Genentech Inc | anticorpo humanizado que liga cd20 humano, composição, artigo manufaturado, método de indução da apoptose, método de tratamento de câncer cd20 positivo, métodos de tratamento de doenças autoimunes, ácidos nucléicos isolados, vetores de expressão, células hospedeiras, método para a produção de um anticorpo 2h7 humanizado, polipeptídeo isolado, formulação líquida, método de tratamento de artrite reumatóide (ra) e anticorpos de ligação de cd20 humanizados |
JP2007503439A (ja) | 2003-08-22 | 2007-02-22 | アクティブバイオティクス インコーポレイティッド | リファマイシンアナログおよびそれらの使用法 |
AU2004279742A1 (en) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Fused protein composition |
CA2542125A1 (en) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase |
BR122018071808B8 (pt) * | 2003-11-06 | 2020-06-30 | Seattle Genetics Inc | conjugado |
JPWO2005053742A1 (ja) | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | 抗体組成物を含有する医薬 |
CN1918172B (zh) | 2003-12-23 | 2011-09-14 | 活跃生物工艺学公司 | 利福霉素类似物及其用途 |
EP1718667B1 (en) | 2004-02-23 | 2013-01-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
CA2580141C (en) | 2004-09-23 | 2013-12-10 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
US8343928B2 (en) | 2005-07-07 | 2013-01-01 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine side-chain replacements at the C-terminus |
WO2007008848A2 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
WO2007096703A2 (en) * | 2005-08-11 | 2007-08-30 | Targanta Therapeutics Inc. | Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections |
US7547692B2 (en) | 2005-12-14 | 2009-06-16 | Activbiotics Pharma, Llc | Rifamycin analogs and uses thereof |
ES2369946T3 (es) | 2007-03-01 | 2011-12-09 | Symphogen A/S | Procedimiento para clonación de anticuerpos análogos. |
AU2008251608B2 (en) | 2007-05-08 | 2014-03-27 | Genentech, Inc. | Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates |
NZ584514A (en) | 2007-10-19 | 2012-07-27 | Genentech Inc | Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates |
JP2011519974A (ja) | 2008-05-12 | 2011-07-14 | ストロックス バイオファーマスーティカルズ,エルエルシー | 黄色ブドウ球菌(Staphylococcusaureus)に特異的な抗体製剤 |
US8524691B2 (en) | 2008-08-13 | 2013-09-03 | The Medicines Company | Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections |
WO2010042481A1 (en) | 2008-10-06 | 2010-04-15 | University Of Chicago | Compositions and methods related to bacterial eap, emp, and/or adsa proteins |
CN102666583B (zh) * | 2009-07-15 | 2015-11-25 | Aimm医疗股份公司 | 革兰氏阳性细菌特异性结合化合物 |
CA2799540A1 (en) | 2010-06-08 | 2011-12-15 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
PL2678037T3 (pl) | 2011-02-25 | 2015-05-29 | Lonza Ag | Rozgałęziony łącznik do koniugatów białko-lek. |
WO2013168965A2 (ko) * | 2012-05-07 | 2013-11-14 | 목암생명공학연구소 | 포도상구균 감염 예방용 백신 조성물 |
-
2014
- 2014-05-30 ES ES14732800T patent/ES2793174T3/es active Active
- 2014-05-30 BR BR112015029838A patent/BR112015029838A2/pt not_active Application Discontinuation
- 2014-05-30 UA UAA201511604A patent/UA120088C2/uk unknown
- 2014-05-30 EP EP14732800.9A patent/EP3004162B1/en active Active
- 2014-05-30 EA EA201592078A patent/EA201592078A1/ru unknown
- 2014-05-30 HU HUE14732800A patent/HUE050451T2/hu unknown
- 2014-05-30 PE PE2015002538A patent/PE20160715A1/es unknown
- 2014-05-30 KR KR1020157033622A patent/KR20160015227A/ko not_active Application Discontinuation
- 2014-05-30 JP JP2016517056A patent/JP6469094B2/ja not_active Expired - Fee Related
- 2014-05-30 AU AU2014273939A patent/AU2014273939B2/en not_active Ceased
- 2014-05-30 RS RS20200548A patent/RS60256B1/sr unknown
- 2014-05-30 CN CN201480037322.1A patent/CN105358573B/zh not_active Expired - Fee Related
- 2014-05-30 MY MYPI2015002849A patent/MY177774A/en unknown
- 2014-05-30 LT LTEP14732800.9T patent/LT3004162T/lt unknown
- 2014-05-30 MX MX2015016405A patent/MX369022B/es active IP Right Grant
- 2014-05-30 EP EP18169959.6A patent/EP3381939A1/en not_active Withdrawn
- 2014-05-30 PL PL14732800T patent/PL3004162T3/pl unknown
- 2014-05-30 SG SG11201509839TA patent/SG11201509839TA/en unknown
- 2014-05-30 CN CN202011074088.3A patent/CN112430266A/zh active Pending
- 2014-05-30 MA MA38686A patent/MA38686A1/fr unknown
- 2014-05-30 WO PCT/US2014/040324 patent/WO2014194247A1/en active Application Filing
- 2014-05-30 CA CA2910029A patent/CA2910029A1/en not_active Abandoned
- 2014-05-30 PT PT147328009T patent/PT3004162T/pt unknown
- 2014-05-30 DK DK14732800.9T patent/DK3004162T3/da active
- 2014-05-30 SI SI201431578T patent/SI3004162T1/sl unknown
-
2015
- 2015-10-20 IL IL242175A patent/IL242175B/en active IP Right Grant
- 2015-10-27 ZA ZA2015/07977A patent/ZA201507977B/en unknown
- 2015-11-25 CR CR20150626A patent/CR20150626A/es unknown
- 2015-11-26 PH PH12015502636A patent/PH12015502636A1/en unknown
- 2015-11-27 MX MX2019012708A patent/MX2019012708A/es unknown
- 2015-11-30 CL CL2015003496A patent/CL2015003496A1/es unknown
-
2016
- 2016-07-29 HK HK16109071.5A patent/HK1220982A1/zh unknown
-
2018
- 2018-11-05 JP JP2018208440A patent/JP2019054801A/ja active Pending
-
2019
- 2019-12-11 AU AU2019279986A patent/AU2019279986A1/en not_active Abandoned
-
2020
- 2020-05-19 HR HRP20200812TT patent/HRP20200812T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR21C1030I2 (fr) | Conjugué anticorps anti-her2-médicament | |
CL2015003496A1 (es) | Anticuerpos teicoicos anti-pared y conjugados. | |
CL2015001924A1 (es) | Anticuerpos anti-pdgfr-beta y usos relacionados. | |
CL2016001646A1 (es) | Anticuerpos y fragmentos anti-vista | |
CL2016000680A1 (es) | Formulaciones de anticuerpos anti-pdl1. | |
CL2016000251A1 (es) | Anticuerpos anti-activina y usos de los mismos | |
DK2970460T3 (da) | Anti-IL-33-antistoffer og anvendelser deraf | |
IL241277A0 (en) | Antibody-drug conjugates | |
DK3336106T3 (da) | Anti-fcrh5-antistoffer | |
BR112016021717A2 (pt) | anticorpos anti-egfr e conjugados anticorpo-fármaco | |
DK3089994T3 (da) | Fabs-in-tandem-immunglobulin og anvendelser deraf | |
DK3083688T3 (da) | Humane anti-cd40 humane antistoffer | |
DK3381943T3 (da) | Anti-kit-antistoffer og anvendelser deraf | |
DK3026062T3 (da) | Anti-pd-1-antistof og anvendelse deraf | |
DK3708583T3 (da) | Ikke-fucosylerede anti-fgfr2iiib-antistoffer | |
DK3480215T3 (da) | Anti-HER2-antistof og konjugat deraf | |
CL2015003481A1 (es) | Conjugados de anticuerpo fármaco | |
CL2015002750A1 (es) | Anticuerpos humanos pac1 | |
CL2015001049A1 (es) | Terapia de combinación de anticuerpos anti-her3 | |
DK3079719T3 (da) | ANTI-SIGLEC-8-antistoffer og fremgangsmåder til anvendelse deraf | |
CL2016000219A1 (es) | Proteinas de fusión terapéutica. | |
DK3041857T3 (da) | Protein a-kromatografi | |
DK3453723T3 (da) | Anti-ASIC1-antistoffer og anvendelser deraf | |
DK3068800T3 (da) | FcRn-specifikke antistoffer | |
DK3154587T3 (da) | Konjugater omfattende et anti-egfr1-antistof |